NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

SLXN

Silexion Therapeutics Corp

Apr 04 • 11:53AM ET

0.8947

Dollar change -0.0453
Percentage change -4.82	%

Healthcare • Biotechnology • Israel • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-19.98	Insider Own	9.05%	Shs Outstand	8.69M	Perf Week	-23.53%
Market Cap	7.78M	Forward P/E	-	EPS next Y	-1.31	Insider Trans	0.00%	Shs Float	7.91M	Perf Month	-26.06%
Income	-13.92M	PEG	-	EPS next Q	-0.22	Inst Own	6.80%	Short Float	5.36%	Perf Quarter	-55.04%
Sales	0.00M	P/S	-	EPS this Y	96.36%	Inst Trans	48.84%	Short Ratio	0.03	Perf Half Y	-81.66%
Book/sh	-2.16	P/B	-	EPS next Y	-36.46%	ROA	-320.05%	Short Interest	0.42M	Perf Year	-99.07%
Cash/sh	0.14	P/C	6.37	EPS next 5Y	59.98%	ROE	-3.78%	52W Range	0.57 - 122.02	Perf YTD	-55.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-286.10%	ROI	-	52W High	-99.27%	Beta	0.09
Dividend TTM	-	Quick Ratio	0.64	Sales past 5Y	0.00%	Gross Margin	-	52W Low	55.60%	ATR (14)	0.14
Dividend Ex-Date	-	Current Ratio	0.64	EPS Y/Y TTM	-73095.97%	Oper. Margin	-	RSI (14)	37.17	Volatility	8.48% 9.64%
Employees	14	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	5.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-41.49%	Payout	-	Rel Volume	0.02	Prev Close	0.94
Sales Surprise	-	EPS Surprise	21.43%	Sales Q/Q	-	Earnings	Mar 18 AMC	Avg Volume	14.06M	Price	0.89
SMA20	-23.12%	SMA50	-27.20%	SMA200	-96.29%	Trades		Volume	112,712	Change	-4.82%

Mar-28-25 08:30AM	Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data (GlobeNewswire)
Mar-21-25 08:30AM	Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference (GlobeNewswire)
Mar-18-25 04:29PM	Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -11.20%
Mar-17-25 08:15AM	PESG Report: Silexion Therapeutics Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis Signaling a Potential Paradigm Shift in Cancer Treatment (Business Wire)
Mar-05-25 08:30AM	Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models (GlobeNewswire) +30.63%
08:30AM	Loading…
Mar-03-25 08:30AM	PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational (Business Wire)
Feb-25-25 08:30AM	Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204 (GlobeNewswire) +64.00%
Jan-29-25 05:30PM	Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds (GlobeNewswire) +132.59% -34.71%
09:59AM	PESG Report: Silexion Therapeutics Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market (Business Wire)
Jan-28-25 08:29AM	Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models (GlobeNewswire) +132.76%
Jan-16-25 11:04AM	PESG Market Update: Silexion Therapeutics SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments (Business Wire) -39.74%
Jan-15-25 08:00PM	Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering (GlobeNewswire) -11.86%
04:01PM	Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies (GlobeNewswire)
Jan-13-25 07:50AM	Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Dec-18-24 06:35AM	Silexion Therapeutics, Evonik collaborate on siRNA formulation development (TipRanks) -26.21%
09:36AM	Loading…
Dec-17-24 09:36AM	PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises (Business Wire) -10.77%
06:30AM	Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development (GlobeNewswire)
Dec-10-24 08:30AM	Silexion Therapeutics Appoints Renowned Cancer Therapeutics Expert Prof. Amnon Peled to Board of Directors (GlobeNewswire)
Nov-22-24 04:30PM	Silexion Therapeutics Announces 1-for-9 Reverse Share Split (GlobeNewswire)
Nov-20-24 08:30AM	Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference (GlobeNewswire) +47.26%
Nov-14-24 08:30AM	Silexion Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (ACCESSWIRE) -8.73%
Oct-09-24 05:35PM	Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit (ACCESSWIRE) -11.93% -5.98%
Oct-01-24 06:45AM	Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies (Business Wire) +5.90%
Sep-24-24 07:30AM	Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER in Non-Resectable Pancreatic Cancer (Business Wire) -16.28%
Sep-09-24 07:32AM	PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers (Business Wire) +11.61%
Sep-03-24 04:05PM	Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference (GlobeNewswire) -24.66% -10.98%
Aug-15-24 04:05PM	Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination (GlobeNewswire) -13.21% -79.39%

Silexion Therapeutics Corp. engages in the discovery and development of treatments for KRAS-driven cancers. The company is headquartered in Modiin, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SLXN

Silexion Therapeutics Corp

Upgrade your FINVIZ experience